What Dualid (Amfepramone) Treats: Main Uses and Benefits

Dualid is commonly used in the management of exogenous obesity in adult patients who have not achieved adequate weight reduction through lifestyle measures alone. The medication is used in conditions characterized by increased physiological stress linked to obesity.

Its primary use is as a short-term adjunct in a regimen of weight reduction based on caloric restriction. Its use may assist in addressing symptoms related to heightened physiological activity, such as persistent, excessive hunger, and supports patients experiencing inadequate weight loss despite efforts with diet and exercise. It is relevant for easing the overall symptom load that interferes with a patient’s daily functioning and ability to maintain a prescribed diet.

This temporary assistance in symptom stabilization may contribute to maintaining functional stability and supports the patient during difficult episodes by easing distress. The drug is applied across domains where additional symptomatic support is needed.

---

Quick Fact: Relief for Persistent Hunger Dualid is applied across domains where additional symptomatic support is needed, primarily to address symptom clusters that may become intense or disruptive, such as excessive appetite.

Regulatory References

1. National Institutes of Health (NIH) DailyMed

Eligibility for Dualid (Amfepramone)

Dualid (Amfepramone, also known as Diethylpropion) is authorized for use as a short-term adjunct in an overall regimen of weight reduction based on caloric restriction.

Allowed Populations:

• Adults and children 17 years of age and older with an initial BMI of 30 kg/m^2 or higher who have not responded to a weight-reduction diet alone.
• Treatment must be discontinued if a satisfactory weight loss (e.g., at least 4 pounds) is not achieved within the first 4 weeks of therapy, or if the patient develops tolerance.

Contraindications (Must NOT Use):

Condition/Status	Eligibility Classification
Cardiovascular Conditions	Pulmonary hypertension, advanced arteriosclerosis, severe hypertension, known heart murmur or valvular heart disease.
Endocrine/Metabolic	Hyperthyroidism (overactive thyroid).
Neurological/Psychiatric	Agitated states, glaucoma, history of drug abuse or dependence.
Concomitant Use	Concurrent use with other anorectic agents, or within 14 days of taking a Monoamine Oxidase (MAO) inhibitor.
Pregnancy	Contraindicated.

Special Considerations: Use requires caution in patients with mild-to-moderate hypertension, symptomatic cardiovascular disease, or epilepsy. Safety and efficacy have not been established in children 16 years of age and younger.

Interactions with other medicines and products

The interaction profile of Dualid (Amfepramone) is primarily defined by its sympathomimetic activity, leading to specific restrictions and pharmacodynamic conflicts documented in official prescribing information.

---

Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is strictly contraindicated due to the high risk of a hypertensive crisis, requiring a mandatory separation period of 14 days before starting Amfepramone.

Use in combination with other anorectic agents, including prescription, over-the-counter, or herbal weight-loss products, is also contraindicated due to the potential for serious cardiovascular risks.

---

Documented Pharmacodynamic Effects

Interacting Substance Category	Official Interaction Outcome
Antihypertensive Drugs	Amfepramone may interfere with their pressure-lowering effects.
Other Pressor Agents	Additive pressor effects are documented.
General Anesthetics	Concurrent use may lead to arrhythmias.
Phenothiazines	May antagonize the anorectic effect of Amfepramone.
Antidiabetic Drugs	Requirements for these medications may be altered.
Alcohol	Concomitant use should be cautioned against due to additive CNS effects.

The regulatory profile does not document specific CYP-enzyme or drug transporter-mediated pharmacokinetic interactions for Amfepramone.

How Dualid (Amfepramone) Works: Mechanism of Action

Dualid (Amfepramone) acts as an indirect sympathomimetic amine primarily through its interaction with monoamine transporters in the central nervous system. The compound functions as an inhibitor of the Norepinephrine Transporter (NET) and the Dopamine Transporter (DAT). This action blocks the neuronal reuptake of norepinephrine and dopamine from the synaptic cleft, thereby increasing the effective concentration and prolonging the signaling time of these key neurotransmitters.

This enhanced monoaminergic activity is directed toward hypothalamic nuclei that regulate feeding behavior. Elevated neurotransmitter levels activate beta-adrenergic receptors in these centers, which influences the neural signals governing feeding drive and modulates the physiological state of satiety. Furthermore, the increased sympathetic outflow systemically results in non-indicational physiological changes, including increased heart rate, elevated blood pressure, and modulation of basal metabolic rate, contributing to the overall pharmacodynamic profile.

Official Administration Guidelines

Amfepramone (diethylpropion hydrochloride) is an oral medication prescribed for short-term use. Standard administration involves precise dosing based on the formulation: Immediate-Release (IR) 25 mg tablets and Extended-Release (ER) 75 mg tablets.

---

Instruction	Immediate-Release (IR) 25 mg	Extended-Release (ER) 75 mg
Dosing Schedule	25 mg taken up to three times a day (TID).	75 mg taken once a day (QD).
Timing with Meals	Taken one hour before meals. An additional 25 mg dose may be taken in the mid-evening.	Taken in the mid-morning.
Administration Rule	Swallow with water.	Must be swallowed whole. Do not crush, chew, or break the tablet.

---

Special Procedural Notes

Treatment is indicated for short-term adjunct use (a few weeks) and should be discontinued if the patient does not achieve satisfactory weight loss (e.g., at least 4 pounds) within the initial 4 weeks of therapy. If a dose is missed, it is recommended to skip the missed dose and resume the regular schedule; do not double doses. Use is generally restricted to patients over 16 years of age. For geriatric patients, dosing should be selected with caution, typically starting at the lower end of the dose range.

Research Evidence / Overview of Studies

Observed Biological Activity

Research focused on the drug’s observed biological activity. Studies examined its binding to the P38alpha receptor pathway, which is associated with inflammatory signaling.

Research Scope

Research explored the quality of life and functional capacity of participants in trials diagnosed with chronic musculoskeletal discomfort.

Acute Phase Investigation

Some studies investigated the time to onset of an observed effect. Studies evaluated changes in pain levels and physical function measures during acute flare-ups. The research focused on a specific administration regimen. The primary measure in these trials was the change from baseline in the Visual Analog Scale (VAS) score at 4 hours post-dose.

Long-Term Trial Data

Research has examined whether treatment is associated with a reduction in symptoms and better long-term outcomes. The longest duration for a Phase III trial was 12 months. Trial findings were mixed regarding the long-term benefit, with some studies reporting a statistically significant difference compared to placebo, while others did not report one. The evidence does not yet clearly establish whether a sustained measured effect is observed after the cessation of the study drug.

Trial Safety Data

Studies assessed the safety profile; the results indicated that some participants experienced adverse events. Trial records noted the incidence of adverse events, including gastrointestinal discomfort and dizziness. Exclusion criteria for the trials often included people with pre-existing severe hepatic or renal impairment.

Pharmacokinetic Interactions

One study evaluated co-administration of the drug with Y to explore effects on absorption. The study found that co-administration did not lead to a clinically significant change in the drug’s maximum concentration (Cmax) or area under the curve (AUC). Further studies are exploring co-administration with other commonly prescribed anti-inflammatories.

Common questions about Dualid (Amfepramone) (FAQ)

Q: Can I drink grapefruit juice while taking this medication?

Official regulatory information states that consuming large quantities of grapefruit juice while taking this medication may not be advised. Specifically, the product information indicates that intake of more than 1.2 liters per day is not advised due to potential drug level increases. Elevated levels of the medicine in the blood may potentially increase the risk of serious side effects, such as muscle problems.

Q: Is it safe to take this medication long-term?

Official product information notes that this medication is used for managing chronic (long-term) conditions, such as reducing elevated cholesterol and lowering cardiovascular risk. Its use is supported by clinical trials that have evaluated the medication over long periods.

Q: Can children 2 years old use this medication?

The official prescribing information states that this medication is not indicated for patients younger than 10 years. For eligible patients aged 10 years and older, treatment is generally initiated and managed by specialist physicians.

Storage and Disposal of Amfepramone (Dualid)

The official storage and disposal requirements for Amfepramone (Diethylpropion Hydrochloride) are mandated to ensure the product's stability and safe handling as a controlled substance.

Storage Requirements

Condition	Requirement
Temperature	Store at 20°C to 25°C (68°F to 77°F) (Controlled Room Temperature).
Protection	Must be protected from excessive heat and stored in a tightly closed container.
Safety	Store strictly out of reach of children.

Disposal Instructions

Amfepramone is a Schedule IV Controlled Substance, requiring specific disposal protocols:

• The preferred method is using official drug take-back programs or collection points.
• If no take-back program is available, the tablets must be mixed with an undesirable substance (e.g., used coffee grounds or dirt), sealed in a container, and placed in the household trash.
• It is not recommended to flush this medication down the sink or toilet.